Integra Therapeutics closes a new investment of €1.5-million with the addition of Columbus Venture Partners to seed round
- The biotechnology firm completes the seed round funding with a total of €6 million led last December by AdBio Partners, Invivo Capital and Takeda Ventures
- The Integra Therapeutics gene writing platform is one of the most promising in the world for improving gene therapy to treat genetic diseases and cancer
Integra Therapeutics, a biotechnology company that creates next generation gene writing tools, has closed an additional €1.5-million investment from venture capital firm Columbus Venture Partners. This investment comes on top of the €4.5 million Integra Therapeutics raised last December from AdBio Partners, Invivo Capital and Takeda Ventures and completes its seed round in line with the company’s set goals.
The new funds will go to support development of the FiCAT platform prototype and preclinical validation with in vivo and ex vivo models. FiCAT is one of the most promising
gene writing technologies in the world, as it addresses the current technical limitations of gene therapies (gene size, precision and stability) to make them safer and more efficient at preventing and treating genetic diseases and cancers with unmet medical needs. The investment from Columbus VP comes through its third fund, Columbus Life Science Fund III FCR, which was presented in 2021 with €120 million. Damià Tormo, managing partner of Columbus VP, will join the Integra Therapeutics board of directors.
“We thank Columbus VP for their trust and enthusiasm and look forward to working with them to achieve safer, more efficient gene therapies for patients as quickly as possible. In rare diseases alone, we know that 72% are caused by genetic defects and that there isn’t currently any effective therapeutic treatment for most of them,” explains Dr Avencia Sánchez-Mejías, cofounder and CEO of Integra Therapeutics.
“We believe Integra Therapeutics, with ground breaking science, is destined to be one of the benchmark biotechnology firms in gene writing over the coming years. We can’t wait to start working with the management team at Integra and the current partners,” noted Damià Tormo.
Integra Therapeutics also recently brought Professor George Church, a pioneer in human gene editing, on board to join the company’s scientific advisory board.